THE ADVISORY BOARD COMPANY REPORTS FISCAL 2006 SECOND QUARTER RESULTS
Company Reports Quarterly Revenue and Contract Value Growth of 17%; New Research Program Announced
WASHINGTON, D.C.— (October 26, 2005) — The Advisory Board Company (NASDAQ: ABCO) today announced financial results for the second quarter of its fiscal year ending March 31, 2006. For the quarter, revenues increased 17% to $40.5 million, from $34.7 million for the second quarter of fiscal 2005. Net income was $7.0 million, or $0.35 per diluted share, compared to $5.9 million, or $0.31 per diluted share, for the same period a year ago.
Revenues for the six months ended September 30, 2005, increased 17% to $79.2 million, from $67.7 million in the six months ended September 30, 2004. Net income for the period was $13.7 million, or $0.68 per diluted share, compared to $11.5 million, or $0.60 per diluted share, for the same period a year ago. Contract value grew 17% to $159.8 million as of September 30, 2005, up from $136.9 million as of September 30, 2004.
Frank Williams, Chairman and Chief Executive Officer of The Advisory Board Company, commented, “We are very pleased with our financial results as we delivered revenue and contract value growth of 17% and net income growth of 19%. Our performance was driven by cutting-edge research agendas and continued program innovation, which led to strong renewal performance and continued growth across our program portfolio. Most importantly, we continue to see strong attachment to our model of providing proven best practices to address healthcare’s complex array of strategic and operational issues.”
He added, “I am also pleased to announce our latest launch, the Clinical Technology Assessment Program. This new best practice research program offers senior marketing and planning executives from hospitals and medical device companies the tools to bring rigorous business discipline to the evaluation of emerging clinical technologies, as well as a broader assessment of the market landscape across the major clinical lines of business. By offering a deep understanding of specific technologies, physician adoption patterns and reimbursement trends, we are able to provide our members with insight across an expansive landscape ranging from neurology and orthopedics to gastroenterology and general surgery. The program’s cutting-edge research agenda is enriched by leveraging a robust forecasting database to tailor the research to each specific business situation, ensuring that the information is actionable and relevant for each member institution. As always, we are pleased to have worked with a stellar group of charter advisors, including Yale New Haven Health System, UNC Health Care, University of Michigan Health System, Alexian Brothers Hospital Network, Medtronic, Riverain Medical Group, Aspect Medical Systems and Boston Scientific Corporation. The program is off to a strong start, and we are very excited about its potential.”
1
Share Repurchase
During the three months ended September 30, 2005, the Company repurchased 175,143 shares of its common stock at a total cost of approximately $8.8 million. To date, the Company has repurchased 1,988,534 shares at a total cost of approximately $72.9 million and has $27.1 million available under the program for future share repurchases.
Outlook for Remainder of Calendar Year 2005
The Company reiterated its previously announced guidance for the next calendar quarter of $41.3 million of revenue, and adjusted earnings per diluted share of $0.37. Combined with the results from the first three quarters of calendar year 2005, the Company’s full calendar year revenue and adjusted earnings per diluted share guidance is $158.3 million and $1.41, respectively. Adjusted earnings per diluted share excludes stock option related expense.
The Company will hold an investor conference call to discuss its second quarter performance this evening, October 26, 2005, at 6:00 p.m. Eastern Daylight Time. The conference call will also be available via live web cast on the Company’s web site atwww.advisoryboardcompany.com in the section entitled “Investor Information” found under the tab “About Us.” To participate by telephone, the dial-in number is 800-299-6183 and the access code is 31186052. Investors are advised to dial in at least five minutes prior to the call to register. The web cast will be archived for seven days: from 8:00 p.m. Wednesday, October 26, until 8:00 p.m. Wednesday, November 2, 2005.
About The Advisory Board Company
The Advisory Board Company provides best practices research and analysis to the health care industry, focusing on business strategy, operations and general management issues. The Company provides best practices and research through discrete annual programs to a membership of more than 2,500 hospitals, health systems, pharmaceutical and biotech companies, health care insurers, and medical device companies in the United States. Each program typically charges a fixed annual fee and provides members with best practices, research reports, executive education and other supporting research services.
The Company believes its calculations of adjusted income from operations, net income and diluted earnings per share provide additional information about the Company’s ongoing operating performance as well as additional information to compare to prior periods. The Company is not able to reconcile its outlook for the remainder of calendar year 2005 to GAAP as stock option related expense is dependent upon a number of unknown factors, including the extent (if any) to which employee stock options are exercised and future stock price.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You are hereby cautioned that these statements may be affected by certain factors, among others, set forth below and in the Company’s filings with the Securities and Exchange Commission, and consequently, actual operations and results may differ materially from the results discussed in the forward-looking statements. Factors that could cause actual results to differ materially from those indicated by forward-looking statements include, among others, the dependence on renewal of membership based services, dependence on key personnel, the need to attract and retain qualified personnel, management of growth, new product development, competition, risks associated with anticipating market trends, industry consolidation, variability of quarterly operating results and various factors that could affect the estimated tax rate. These factors are discussed more fully in the Company’s filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.
# # #
2
THE ADVISORY BOARD COMPANY UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS AND OPERATING STATISTIC (In thousands, except per share data)
Three Months Ending
Selected
Six Months Ending
Selected
September 30,
Growth
September 30,
Growth
2005
2004
Rates
2005
2004
Rates
Statements of Operations
Revenues
$
40,487
$
34,680
16.7
%
$
79,234
$
67,705
17.0
%
Cost of services
17,487
14,166
33,996
27,840
Member relations and marketing
8,229
6,773
16,294
13,289
General and administrative
4,035
4,216
7,859
8,143
Depreciation and loss on disposal of assets
451
600
884
992
Income from operations
10,285
8,925
20,201
17,441
Interest income
1,412
916
2,807
1,809
Income before provision for income taxes
11,697
9,841
23,008
19,250
Provision for income taxes
(4,737
)
(3,986
)
(9,318
)
(7,797
)
Net income
$
6,960
$
5,855
$
13,690
$
11,453
Earnings per share
Basic
$
0.36
$
0.34
$
0.71
$
0.65
Diluted
$
0.35
$
0.31
12.9
%
$
0.68
$
0.60
13.3
%
Weighted average common shares outstanding
Basic
19,093
17,409
19,158
17,604
Diluted
20,020
18,940
20,006
19,181
Percentages of Revenues
Cost of services
43.2
%
40.8
%
42.9
%
41.1
%
Member relations and marketing
20.3
%
19.5
%
20.6
%
19.6
%
General and administrative
10.0
%
12.2
%
9.9
%
12.0
%
Depreciation and loss on disposal of assets
1.1
%
1.7
%
1.1
%
1.5
%
Income from operations
25.4
%
25.7
%
25.5
%
25.8
%
Net income
17.2
%
16.9
%
17.3
%
16.9
%
Contract Value (at end of period) (1)
$
159,810
$
136,916
16.7
%
(1) We define “Contract value” as the aggregate annualized revenue attributable to all agreements in effect at any given point in time, without regard to the initial term or remaining duration of any such agreements.
3
THE ADVISORY BOARD COMPANY CONSOLIDATED BALANCE SHEETS (In thousands)
September 30,
March 31,
2005
2005
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
10,949
$
27,867
Marketable securities
3,947
3,003
Membership fees receivable, net
25,302
21,320
Prepaid expenses and other current assets
2,471
2,430
Deferred income taxes
21,623
19,774
Total current assets
64,292
74,394
Fixed assets, net
8,684
9,023
Intangible assets, net
6,236
—
Deferred incentive compensation and other charges
6,490
6,189
Deferred income taxes, net of current portion
22,140
33,489
Marketable securities
130,391
122,044
Total assets
$
238,233
$
245,139
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Deferred revenues
$
76,489
$
82,262
Accounts payable and accrued liabilities
11,023
8,733
Accrued incentive compensation
6,241
7,820
Total current liabilities
93,753
98,815
Other long-term liabilities
873
1,010
Total liabilities
94,626
99,825
Stockholders’ equity:
Common stock
199
199
Additional paid-in capital
142,760
142,040
Retained earnings
41,615
27,925
Accumulated elements of comprehensive income
(1,193
)
(1,273
)
Treasury stock
(39,774
)
(23,577
)
Total stockholders’ equity
143,607
145,314
Total liabilities and stockholders’ equity
$
238,233
$
245,139
4
THE ADVISORY BOARD COMPANY UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)
Six Months Ended September 30,
2005
2004
Cash flows from operating activities:
Net income
$
13,690
$
11,453
Adjustments to reconcile net income to net cash provided by
operating activities -
Depreciation
884
876
Amortization of intangible assets acquired
43
—
Loss on disposal of fixed assets
—
116
Deferred income taxes
8,827
7,771
Amortization of marketable securities premiums
429
362
Changes in operating assets and liabilities:
Member fees receivable
(3,831
)
(5,440
)
Prepaid expenses and other current assets
(24
)
95
Deferred incentive compensation and other charges
(411
)
(81
)
Deferred revenues
(5,920
)
(4,838
)
Accounts payable and accrued liabilities
840
(311
)
Accrued incentive compensation
(1,579
)
(1,885
)
Other liabilities
(242
)
1,264
Net cash flows provided by operating activities
12,706
9,382
Cash flows from investing activities:
Purchases of property and equipment
(460
)
(3,800
)
Purchase of marketable securities
(15,933
)
(13,850
)
Redemption of marketable securities
6,400
10,713
Cash paid for acquisition, net of cash acquired
(3,596
)
—
Net cash flows used in investing activities
(13,589
)
(6,937
)
Cash flows from financing activities:
Proceeds on issuance of stock from exercise of stock options
344
551
Proceeds on issuance of stock under ESPP
189
148
Repayment of debt assumed in acquisition
(371
)
—
Purchases of treasury stock
(16,197
)
(26,621
)
Net cash flows used in financing activities
(16,035
)
(25,922
)
Net decrease in cash and cash equivalents
(16,918
)
(23,477
)
Cash and cash equivalents, beginning of period
27,867
41,389
Cash and cash equivalents, end of period
$
10,949
$
17,912
5
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.
